http://www.fpnotebook.com/
CarbamazepineAka: Tegretol
- Indication
- Simple Partial Seizures
- Complex Partial Seizures
- Generalized Tonic Clonic Seizures
- Trigeminal Neuralgia
- Bipolar Disorder
- Frequently reserved for use as a second agent
- Resistant Schizophrenia
- Restless Leg Syndrome
- Psychosis in Dementia
- Post-Traumatic Stress Disorder
- Contraindications
- MAO inhibitor use within last 14 days
- Bone Marrow depression
- Pregnancy
- Precautions
- Do not use in Asian patients unless they are negative for HLA-B1502
- Risk of Steven's Johnson: 5% if HLA-B1502 positive
- FDA has issued a black box warning
- Man (2007) Epilepsia 48(5):1015
- Adverse Effects: Dose related
- Gradual tolerance to side effects
- Lethargy
- Nausea and Vomiting
- Tremor
- Ataxia
- Diplopia
- Adverse Effects: Other
- Morbilliform rash
- Leukopenia
- Agranulocytosis
- Aplastic Anemia
- Cardiac conduction abnormality (increases A-V delay)
- Hyponatremia (SIADH risk in elderly)
- Liver failure
- Osteoporosis
- Serum Sickness
- Stevens-Johnson Syndrome
- Drug Interactions (Numerous)
- Substrate of Cytochrome P450 2C8/9
- Substrate of Cytochrome P450 3A4
- Induces Cytochrome P450 1A2
- Induces Cytochrome P450 2B6
- Induces Cytochrome P450 2C8/9
- Induces Cytochrome P450 2C19
- Induces Cytochrome P450 3A4
- Dose: General
- Titrate dose to serum concentration and effect
- Target serum concentration: 4-12 mcg/ml
- Observe closely for concentration 8 mcg/ml or higher
- Toxic serum concentration: >15 mcg/ml
- Dose: Adults
- Seizure Disorder
- Initial: 200 mg PO bid
- Increase by 200 mg/day increments weekly
- Target: 800-1200 mg/day divided tid - qid
- Trigeminal Neuralgia
- Initial: 100 mg PO bid
- Increase by 100 mg/day increments weekly
- Target: 400-800 mg/day divided bid
- Dose: Elderly
- Initial: 100 mg PO bid
- Increase by 100 mg/day increments weekly
- Target: 400-1000 mg/day divided tid - qid
- Monitoring: Periodic labs
- Complete Blood Count with Platelet Count
- Serum Iron
- Liver Function Test
- Urinalysis
- Serum Sodium
- Blood Urea Nitrogen
- Thyroid Stimulating Hormone
- Serum carbamazepine level
|
|---|
| Definition (MSH) | An anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of PHENYTOIN; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. |
| Definition (CSP) | anticonvulsant and antineuralgic used in the treatment of pain associated with trigeminal neuralgia and in epilepsy manifested by tonic-clonic and partial seizures. |
| Definition (PDQ) | A tricyclic compound chemically related to tricyclic antidepressants (TCA) with anticonvulsant and analgesic properties. Carbamazepine exerts its anticonvulsant activity by reducing polysynaptic responses and blocking post-tetanic potentiation. Its analgesic activity is not understood; however, carbamazepine is commonly used to treat pain associated with trigeminal neuralgia. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42418&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42418&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C341" NCI Thesaurus) |
| Definition (NCI) | A tricyclic compound chemically related to tricyclic antidepressants (TCA) with anticonvulsant and analgesic properties. Carbamazepine exerts its anticonvulsant activity by reducing polysynaptic responses and blocking post-tetanic potentiation. Its analgesic activity is not understood; however, carbamazepine is commonly used to treat pain associated with trigeminal neuralgia. |
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | Carbamazepine, CARBAMAZEPINE PREPARATION, Carbamazepine product |
| Spanish | carbamacepina, carbamazepina |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree